DEBIO 0513
Alternative Names: PTR-262; PTR-262-MGLatest Information Update: 12 Aug 2010
At a glance
- Originator DeveloGen
- Class
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Myasthenia gravis
Most Recent Events
- 25 Sep 2006 DEBIO 0513 has received Orphan Drug Status in Europe for the treatment of Myasthenia gravis
- 18 Aug 2005 DEBIO 0513 has been licensed to Debiopharm worldwide for the treatment of Myasthenia gravis
- 14 Jun 2004 Peptor has been acquired by, and merged into, DeveloGen